<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00148642</url>
  </required_header>
  <id_info>
    <org_study_id>5003A</org_study_id>
    <nct_id>NCT00148642</nct_id>
  </id_info>
  <brief_title>Silver-Coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)</brief_title>
  <acronym>NASCENT</acronym>
  <official_title>Multi-center Clinical Trial of the Bard Silver-coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the use of a silver-coated endotracheal tube
      (ETT) can reduce the incidence and/or delay the time of onset of VAP when compared to a non
      silver-coated ETT in patients who have been mechanically ventilated for &gt;= 24 hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nosocomial pneumonia is the leading cause of death from hospital-acquired
      infections.Ventilator associated pneumonia (VAP) develops in a significant percentage of
      patients who have been ventilated for at least 48 hours, and is associated with high
      morbidity, mortality,and financial costs. Silver is a well-characterized antimicrobial agent,
      and is the active agent in multiple medical products used to reduce or control infection.
      Bard has developed a proprietary antimicrobial ETT, manufactured with a hydrophilic coating
      containing a fine dispersion of silver salts.

      This study compare the incidence and time to onset of VAP in patients intubated for &gt;=24
      hours with a proprietary silver-coated ETT versus those intubated for &gt;= 24 hours with a
      standard non-coated ETT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of microbiologically-confirmed VAP (mVAP), as determined by quantitative culture of bronchoalveolar lavage fluid, in subjects intubated for &gt;=24 hours.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to onset of mVAP in subjects intubated for &gt;=24 hours</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of clinical VAP in subjects intubed for &gt;=24 hours</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of intubation</measure>
    <time_frame>unlimited</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>unlimited</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antibiotic usage</measure>
    <time_frame>unlimited</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay</measure>
    <time_frame>unlimited</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2003</enrollment>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>silver salts coated endotracheal tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>uncoated endotracheal tube</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>silver salts coated endotracheal tube</intervention_name>
    <description>intubation with silver coated tube</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Agento</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>uncoated endotracheal tube</intervention_name>
    <description>intubation</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  expected to be intubated for at least 24 hours

          -  able to sign Informed Consent

        Exclusion Criteria:

          -  symptoms of bronchiectasis

          -  severe hemoptysis

          -  history of cystic fibrosis

          -  intubated &gt; 12 hours within previous 30 days

          -  pregnancy

          -  participating in a competing trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marin H Kollef, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barnes Jewish Hospital, St. Louis, MO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Suburban Hospital</name>
      <address>
        <city>Oak Park</city>
        <state>Illinois</state>
        <zip>60302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic &amp; Foundation</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Mercy Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Audie Murphy VA Medical Center &amp; University Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Baughman RP, Spencer RE, Kleykamp BO, Rashkin MC, Douthit MM. Ventilator associated pneumonia: quality of nonbronchoscopic bronchoalveolar lavage sample affects diagnostic yield. Eur Respir J. 2000 Dec;16(6):1152-7.</citation>
    <PMID>11292122</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>January 14, 2017</last_update_submitted>
  <last_update_submitted_qc>January 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <name_title>Joan Dulin</name_title>
    <organization>CR Bard, Inc</organization>
  </responsible_party>
  <keyword>ventilator-associated pneumonia</keyword>
  <keyword>nosocomial pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

